CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
18F-FLT +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00572728
NCT00572728Phase 2Completed
CompareCT.gov

3'-Deoxy-3'-18F Fluorothymidine PET/CT in Predicting Response To Chemotherapy Before Surgery in Patients With Locally Advanced Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Dec 13, 2007·Updated Dec 30, 2016

In Brief

A Phase 2 clinical trial evaluating CT, 18F-FLT, and 1 other intervention for Stage IIB Breast Cancer and 3 related conditions. Completed, enrolled 90 participants across 27 sites.

Detailed Summary

This phase II trial studies how well 3'-deoxy-3'-18F fluorothymidine (18F-FLT) positron emission tomography (PET)/computed tomography (CT) works in predicting response in patients receiving chemotherapy and undergoing surgery for breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as 18F-FLT PET/CT, may help in learning how well chemotherapy works to kill breast cancer cells before surgery and help doctors plan the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 13, 2007
Enrollment StartDec 1, 2008
Primary CompletionSep 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.6 years ago

Interventions

CTprocedure

Undergo 18F-FLT PET/CT

18F-FLTdrug

Undergo 18F-FLT PET/CT

PETprocedure

Undergo 18F-FLT PET/CT